Nicholas Investment Partners’s AbbVie ABBV Stock Holding History

Nicholas Investment Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-22,800	Closed	-$3.63M	–	191
2023 Q1	$3.63M	Hold	22,800	–	–	0.28%	93
2022 Q4	$3.68M	Hold	22,800	–	–	0.32%	91
2022 Q3	$3.06M	Sell	22,800 -10,380	-31%	-$1.49M	0.28%	100
2022 Q2	$5.08M	Hold	33,180	–	–	0.48%	78
2022 Q1	$5.38M	Buy	33,180 +10,180	+44%	+$1.48M	0.38%	95
2021 Q4	$3.11M	Buy	+23,000	New	+$2.72M	0.2%	141
2021 Q2	–	Sell	-50,000	Closed	-$5.41M	–	200
2021 Q1	$5.41M	Buy	50,000 +10,000	+25%	+$1.07M	0.38%	88
2020 Q4	$4.29M	Buy	+40,000	New	+$3.84M	0.33%	95

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nicholas Investment Partners's ABBV Position: Q2 2023 in Review

Nicholas Investment Partners sold out of AbbVie (ABBV) in Q2 2023, closing a stake of 22,800 shares — an estimated $3.63M sold.

Nicholas Investment Partners first reported a position in ABBV in Q4 2020 and held it in 8 quarters. The position peaked at $5.41M in Q1 2021. 3,076 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.

Nicholas Investment Partners reported no remaining AbbVie position as of Q2 2023 after selling out during the quarter.
Nicholas Investment Partners sold 22,800 AbbVie shares in Q2 2023, an estimated $3.63M.
Nicholas Investment Partners first reported a position in AbbVie in Q4 2020 and held it in 8 quarters.
Nicholas Investment Partners's AbbVie position peaked at $5.41M in Q1 2021.
3,076 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.

Based on Nicholas Investment Partners's 13F filing for Q2 2023, filed 10 Aug 2023.